Researchers at Duke University School of Medicine have developed a new pain relief compound called SBI-810 that offers powerful pain relief without the dangers of opioids. The experimental drug targets a specific receptor on nerves and spinal cord, activating only a specific pain-relief pathway to avoid addiction and side effects.
In tests in mice, SBI-810 worked well on its own and proved effective when used in combination with opioids, reducing the need for higher doses. Unlike traditional opioids, SBI-810 prevented common side effects like constipation and tolerance buildup, which often forces patients to seek stronger and more frequent opioid doses.
The compound’s designer, Ru-Rong Ji, PhD, says it has the potential to be a safer option for treating both short-term and chronic pain. SBI-810 targets the neurotensin receptor 1, using a method called biased agonism that avoids activating other signals linked to addiction or side effects.
In trials, SBI-810 effectively relieved pain from surgical incisions, bone fractures, and nerve injuries, outperforming some existing painkillers like oliceridine. Unlike opioids, it didn’t cause tolerance after repeated use and didn’t lead to sedation or memory problems.
The breakthrough is significant, as the US is facing an opioid crisis with over 80,000 annual deaths, while chronic pain affects one-third of the population. SBI-810’s dual action on both peripheral and central nervous systems could offer a new balance in pain medicine: powerful enough to work yet specific enough to avoid harm.
The study was supported by the National Institutes of Health and the Department of Defense, with multiple patents secured for the discovery. Researchers aim to initiate human trials soon and are optimistic about SBI-810’s potential as a safer pain relief option.
Source: https://medschool.duke.edu/news/experimental-painkiller-could-outsmart-opioids-without-high